Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Impact of a selenium chemoprevention clinical trial on hospital admissions of HIV-infected participants
Division of Disease Prevention, Department of Psychiatry/Behav. Sci., Univ. of Miami School of Medicine, Miami, FL, United States.
Division of Disease Prevention, Department of Psychiatry/Behav. Sci., Univ. of Miami School of Medicine, Miami, FL, United States.
Dept. of Epidemiology/Public Health, Univ. of Miami School of Medicine, Miami, FL, United States.
Division of Disease Prevention, Department of Psychiatry/Behav. Sci., Univ. of Miami School of Medicine, Miami, FL, United States.
Show others and affiliations
2002 (English)In: HIV Clinical Trials, ISSN 1528-4336, Vol. 3, no 6, 483-491 p.Article in journal (Refereed) Published
Abstract [en]

Purpose: To evaluate the impact of selenium chemoprevention (200 μg/day) on hospitalizations in HIV-positive individuals. Method: Data were obtained from 186 HIV+ men and women participating in a randomized, double-blind, placebo-controlled selenium clinical trial (1998-2000). Supplements were dispensed monthly, and clinical evaluations were conducted every 6 months. Inpatient hospitalizations, hospitalization costs, and rates of hospitalization were determined 2 years before and during the trial. Results: At enrollment, no significant differences in CD4 cell counts or viral burden were observed between the two study arms. Fewer placebo-treated participants were using antiretrovirals (p < .05). The total number of hospitalizations declined from 157 before the trial to 103 during the 2-year study. A marked decrease in total admission rates (RR = 0.38; p =.002) and percent of hospitalizations due to infection/100 patients for those receiving selenium was observed (p = .01). As a result, the cost for hospitalization decreased 58% in the selenium group, compared to a 30% decrease in the placebo group (p = .001). In the final analyses, selenium therapy continued to be a significant independent factor associated with lower risk of hospitalization (p = .001). Conclusion: Selenium supplementation appears to be a beneficial adjuvant treatment to decrease hospitalizations as well as the cost of caring for HIV-1-infected patients.

Place, publisher, year, edition, pages
2002. Vol. 3, no 6, 483-491 p.
Keyword [en]
HIV hospitalization, Hospitalization costs, Selenium therapy, abacavir, antiretrovirus agent, CD4 antigen, nucleoside derivative, placebo, proteinase inhibitor, RNA directed DNA polymerase inhibitor, selenium, adjuvant chemotherapy, adult, article, cell count, chemoprophylaxis, clinical trial, controlled clinical trial, controlled study, diet supplementation, dose response, double blind procedure, drug screening, drug use, female, gender, health care cost, highly active antiretroviral therapy, hospital admission, hospital cost, hospitalization, human, human cell, Human immunodeficiency virus 1, Human immunodeficiency virus infection, major clinical study, male, pilot study, priority journal, randomized controlled trial, risk assessment, time, toxicity, treatment outcome, virus load, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, Chemotherapy, Adjuvant, Dietary Supplements, Double-Blind Method, Florida, HIV Infections, Hospital Costs, Humans, Middle Aged, Viral Load
National Category
Immunology
Identifiers
URN: urn:nbn:se:hj:diva-27967DOI: 10.1310/A7LC-7C9V-EWKF-2Y0HPubMedID: 12501132Scopus ID: 2-s2.0-0036865408OAI: oai:DiVA.org:hj-27967DiVA: diva2:854511
Available from: 2015-09-17 Created: 2015-09-17 Last updated: 2015-09-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Lecusay, Robert
In the same journal
HIV Clinical Trials
Immunology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 120 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf